Companies › Nefro Avillion Clinical Development
1 active drug program in 4 registered trials: 3 Phase 1, 1 Phase 2; Gastroenterology, Genitourinary; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Siplizumab T-cell surface antigen CD2 inhibitor | CD2 | Phase 2 | Renal Transplant Failure and Rejection; Autoimmune Liver Disease; Renal Failure; Kidney Failure | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06455280 | Siplizumab | Phase 1 | Autoimmune Liver Disease | Gastroenterology | Dec 2027 |
| NCT07508787 | Siplizumab | Phase 2 | Renal Transplant Failure and Rejection | Genitourinary | Mar 2028 |
| NCT04540380 | Siplizumab | Phase 1 | Renal Failure | Genitourinary | Jan 2029 |
| NCT05900401 | Siplizumab | Phase 1 | Kidney Failure | Genitourinary | Dec 2031 |
Singulera Therapeutics Yaqrit Cerium Pharmaceuticals Noorik Biopharmaceuticals TLC Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.